```json
{
"content": [
{
"type": "paragraph",
"content": "The Soft Tissue Biopsy Devices segmentation by application is primarily divided into diagnostic and therapeutic categories. Diagnostic procedures account for approximately 75% of the market, driven by the high prevalence of oncological conditions requiring precise tissue analysis. Diagnostic biopsies are critical in identifying malignant tumors, inflammatory disorders, and fibrotic changes in soft tissues, necessitating advanced imaging-guided core needle systems. Therapeutic applications, representing 25% of the market, are utilized in ablation therapies and targeted drug delivery to treat localized lesions. While diagnostic procedures dominate due to their prevalence in routine oncology and rheumatology practices, therapeutic applications are witnessing growth from innovations in minimally invasive interventions. The diagnostic segment’s market dominance underscores its role in early detection and staging, whereas therapeutic demand is influenced by evolving interventional techniques. Together, these segments reflect the dual functional utility of Soft Tissue Biopsy Devices, with diagnostic procedures anchoring the market’s stability while therapeutic advancements drive its expansion."
},
{
"type": "paragraph",
"content": "The market taxonomy for Soft Tissue Biopsy Devices is further categorized into core needle biopsy devices and fine needle aspiration biopsy devices. Core needle biopsy devices constitute 65% of the market, leveraging their capacity to obtain larger tissue samples for histopathological analysis, which is essential for accurate cancer staging and fibrosis assessment. These devices are favored in clinical settings requiring detailed cellular architecture. Fine needle aspiration biopsy devices, representing 35% of the market, are preferred for their minimally invasive nature, enabling rapid fluid extraction and cytological evaluation. Their lower procedural complexity and cost-effectiveness drive adoption in primary care diagnostics. The core needle segment benefits from technological advancements in automated biopsy systems and image-guided precision, while the fine needle segment remains stable due to its established role in benign lesion screening. This segmentation highlights the market’s reliance on procedural requirements and diagnostic accuracy, with core needle devices shaping
